Previous studies suggested that distinct phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA) could be determined by presence or absence of antineutrophil cytoplasmic antibodies (ANCA), reflecting predominant vasculitic or eosinophilic processes, respectively. This study explored whether ANCA-based clusters or other clusters can be identified in EGPA.

Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis with interstitial lung disease (DM-ILD) progresses rapidly and has a poor prognosis. Recently, we reported the efficacy of a combination therapy comprising high-dose glucocorticoids (GCs), calcineurin inhibitors (CNIs), and intravenous cyclophosphamide (IVCY) in a multicenter clinical trial (UMIN000014344). In the present

To evaluate knee and multi-joint osteoarthritis (KOA and MJOA) and compare features by sex and race/ethnicity in a population-based cohort.

To study changes in retention of first biologic DMARD therapy over a period of 15 years in an inception cohort of patients with Rheumatoid arthritis (RA), Psoriatic arthritis (PsA) and Ankylosing Spondylitis (AS).

I am very much enjoying your trip down memory lane looking back at important articles in The Journal of Rheumatology I was especially interested in your "Looking Back at the 1990s." I would like to point out an important milestone in The Journal that also took place in the 1990s, that is, the establishment of Pediatric Rheumatology as a section in The Journal.

The American College of Rheumatology (ACR) 2022 guidelines for nonpharmacologic management of rheumatoid arthritis (RA) include a conditional recommendation for physical therapy (PT).1 Known disparities by socioeconomic status (SES) and race and ethnicity in RA prevalence, patient-reported outcomes of function, disease activity, and access exist and persist over time.2,3.

Gout is a common condition characterized by the deposition of monosodium urate (MSU) crystals in articular and nonarticular structures.1 The formation of MSU crystals has been reported in atypical locations such as the eye, nose, spine, and viscera.2.

Children with juvenile dermatomyositis (JDM) and antibodies to melanoma differentiation associated gene 5 (anti-MDA5) are at increased risk of severe disease complications, including interstitial lung disease (ILD). Data regarding treatment of disease complications in this patient population is limited. In this study, we examined the disease course of children with JDM and anti-MDA5 antibodies before

there is no front line everything is war front territory of the organism under attack enemy takes control.

Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease that continues into adulthood in approximately 50% of patients.1 Growth considerations are unique to pediatric-onset disease and can lead to permanent joint damage.

We have previously reported elevated levels of the complement lectin pathway proteins L-ficolin and H-ficolin in axial spondyloarthritis (axSpA) patients compared with healthy controls. The aim of this study was to investigate these biomarkers in a cross-sectional cohort of patients suffering from low back pain (LBP). Furthermore, we aimed to investigate changes in lectin pathway protein levels after

Compare the incidence of total knee arthroplasty (TKA) within the first 5 years after knee OA diagnoses between matched groups of individuals with or without comorbid diagnoses of obesity and/or depression. We hypothesized that the greatest incidence of TKA within 5 years of OA diagnosis would be in the cohort of individuals with combined obesity and depression.

In 2015, the European Alliance of Associations for Rheumatology (EULAR) published recommendations for the use of imaging for the diagnosis and management of spondyloarthritis in clinical practice. These recommendations included the use of ultrasound in patients with psoriatic arthritis (PsA), but the management was not clearly distinguished from spondyloarthritis. We aimed to systematically review

To evaluate the relative prevalence of 8 rheumatic and musculoskeletal diseases (RMDs) across racial/ethnic groups within the Patient-Centered Research Network (PCORnet).

To estimate the prevalence of COVID-19 infection among patients with psoriatic arthritis (PsA), understand patients' perspectives regarding their risk of COVID-19 infection, and evaluate the standard of virtual care offered during the early phases of the pandemic.

Previous studies suggested that distinct phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA) could be determined by presence or absence of antineutrophil cytoplasmic antibodies (ANCA), reflecting predominant vasculitic or eosinophilic processes, respectively. This study explored whether ANCA-based clusters or other clusters can be identified in EGPA.

Acute guttate psoriasis (AGP) is considered an uncommon variant of psoriasis (PsO), characterized as a widespread eruption of erythematous, psoriasiform papules, and plaques on the trunk, extremities, and scalp. Predisposing factors include a family history of PsO, variation in the main PsO susceptibility gene HLA-Cw*0602, and previous infection with viruses or acute β-hemolytic Streptococcus A program

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with the potential to affect multiple organ systems and to lead to significant morbidity and mortality. SLE disproportionately affects women and racial or ethnic minority populations, and health disparities have been described for SLE incidence, prevalence, outcomes, and mortality.1.

Infections during treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) are some of the most frequent adverse events in patients with axial spondyloarthritis (axSpA) and with rheumatic diseases in general. We report a case of a 41-year-old White male with axSpA who developed a Leishmania donovani infection while under treatment with adalimumab (ADA).

We aimed to determine how two definitions of end-stage knee osteoarthritis (esKOA) and each component (knee symptoms, persistent knee pain, radiographic severity, and presence of limited mobility or instability) related to future knee replacement (KR).

Systemic multiple aneurysms are rare findings in granulomatosis with polyangiitis (GPA).1 A 66-year-old woman presented with generalized, subcutaneous nodules and a right leg ulcer of 1-month duration.

This study aimed to explore the experiences of dermatologists and rheumatologists in the early recognition of psoriatic arthritis (PsA) and to identify potential improvements to the current shared-care model.

Rheumatologists are responsible for conducting research on, managing, and treating major autoimmune diseases (AIDs) such as rheumatoid arthritis (RA), systemic lupus erythematosus, and psoriasis. AIDs afflict up to 23.5 million people in the United States.

Long diagnostic delay remains an unsolved problem in many autoimmune rheumatic diseases (ARDs). One of the major contributing factors is poor symptom appraisal and the resulting delayed help-seeking by patients themselves. We thus aimed to understand the experience of symptom appraisal and help-seeking among patients with ARDs in a multi-ethnic urban Asian population and to explore its influencing

Pregnancy in women with systemic lupus erythematosus (SLE) can increase the risk of disease flare, which in turn increases adverse pregnancy outcomes. Maternal adverse pregnancy outcomes include hypertensive disorders, increased cesarean deliveries, and death, whereas fetal adverse outcomes include fetal loss and death, preterm delivery, and intrauterine growth restriction (IUGR).1.

One of the highlights of the 2022 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting was the trainee symposium. Dermatology and rheumatology trainees presented their research related to psoriasis and psoriatic arthritis. This report briefly reviews 5 oral presentations and 15 posters that were selected for this annual meeting. Topics include basic/translational

Young-GRAPPA (Y-GRAPPA) was introduced at the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting. Here we present the 1-year progress of Y-GRAPPA and future plans of this enthusiastic group of young clinicians and early career researchers interested in psoriasis and psoriatic arthritis.

The International Dermatology Outcome Measures (IDEOM) organization presented an update on its progress related to patient-centered outcome measures for psoriasis (PsO) and psoriatic arthritis (PsA) at the 2022 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The Musculoskeletal (MSK) Symptoms working group presented an update on the development

To explore residual disease, defined as substantial symptoms and disease burden despite a remission/low disease activity (described as 'LDA') state, in patients with axial spondyloarthritis (axSpA) and to determine which factors are associated with residual disease.

This post hoc analysis investigated the relationship between paraoxonase-1 (PON1) genotype and activity, and risk of major adverse cardiovascular events (MACE) and malignancies in tofacitinib rheumatoid arthritis (RA) clinical studies.

Describe the efficacy and safety data of children with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with abatacept + methotrexate (MTX) or abatacept monotherapy when prior MTX use was either ineffective or not tolerated.

Obesity is an important comorbidity in axial spondyloarthritis (axSpA). However, the prevalence of obesity in axSpA compared with the general population and associated socioeconomic factors remain unknown.

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) ultrasound (US) steering committee provided an update at GRAPPA's 2022 annual meeting on activities to enable earlier diagnosis of psoriatic arthritis. An update of the Diagnostic Ultrasound Enthesitis Tool (DUET) study included preliminary reliability results for US enthesitis elementary lesions. Common scanning pitfalls

Time passes swiftly and is irrecoverable. In Love in the Time of Cholera, Gabriel García Márquez uses cholera as an analogy for the physical and emotional burdens caused by longing and lovesickness. Just as Florentino Ariza suffers physical and emotional pains from his longing for Fermina Daza, as one might suffer from a disease like cholera, in this issue, Katz and Ye tell a story of longing for equal

At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 annual meeting, the recently published new GRAPPA recommendations were presented and their unique characteristics highlighted, including their truly international approach, the inclusion of patient views from the very beginning, the representation by both rheumatologists and dermatologists, consideration of

A core mission of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) is to provide education about psoriasis and psoriatic arthritis globally. This is a multifaceted endeavor involving in-person and virtual lectures, discussions, podcasts, and archived videos directed toward clinicians and researchers who are involved with psoriatic disease (PsD) care. In partnership

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group-comprising rheumatologists, dermatologists, methodologists, and patient research partners-provided updates at the GRAPPA 2022 annual meeting on its work to evaluate composite outcome measures for PsA. Ten composite outcome measures were

Interleukin (IL)-17 and IL-23 inhibitors are both approved for the treatment of moderate-to-severe plaque psoriasis (PsO), as well as psoriatic arthritis (PsA). In the absence of head-to-head studies, it is not clear which agent is better suited to treat patients with moderate-to-severe PsO and mild PsA. During the 2022 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

People with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Screening patients with PsO for PsA may be helpful in diagnosing PsA early. Dermatologists play a role in assessing their patients with PsO for musculoskeletal symptoms and referring them to a rheumatologist for diagnosis and treatment.

Seven patient research partners (PRPs) attended the 2022 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in person, the first in-person annual meeting since the start of the coronavirus disease 2019 (COVID-19) pandemic. The GRAPPA PRP Network remains engaged and committed to providing dedicated voices supporting delivery of the GRAPPA mission. This

During the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 conference, Drs. Laura Coates and Atul Deodhar debated whether axial psoriatic arthritis (axPsA) is the same as ankylosing spondylitis (AS) with psoriasis. Dr. Coates argued that AS represents a spectrum of disease and that axPsA can be considered within that spectrum. Dr. Deodhar argued that axPsA and AS

Enthesitis is a key disease manifestation in patients with psoriatic arthritis (PsA) that considerably contributes to pain, lower physical function, and reduced quality of life. Clinical assessment of enthesitis lacks sensitivity and specificity, and therefore better methods are urgently needed. Magnetic resonance imaging (MRI) allows detailed assessment of the components of enthesitis, and consensus-based

The 2022 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held from July 14 to 17, 2022, in New York City, New York, USA, and was attended by 420 rheumatologists, dermatologists, basic scientists, allied health professionals, patient research partners, and industry partners from 31 countries. A GRAPPA executive retreat, a Trainee Symposium, and

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) pilot grant awards help support young researchers starting their careers while also encouraging them to develop a focus on psoriatic disease. In this brief report, winners of the 2020 and 2021 awards present the results of their pilot projects.

Prospective comparative effectiveness research (CER) in chronic nonbacterial osteomyelitis (CNO) is lacking. Our objectives were:1) determine the use and safety of each consensus treatment plan (CTP) regimen for CNO, 2) assess the feasibility of using chronic nonbacterial osteomyelitis international registry (CHOIR) data for CER, and 3) develop and validate a CNO clinical disease activity score (CDAS)

We thank the author for their reply1 and appreciate the approach of having clear terminology and standard definitions within clinical practice guidelines or recommendations, that are applicable across specialist groups. A definition of controlled anterior uveitis or quiescent disease is important for treatment decisions, particularly when classifying a patient's disease as failing current therapy and

We appreciate the interest of Wang et al1 in our recently published dataset.2 We would like to clarify some details pertaining to the points made in their letter.1.

To examine postpartum depression (PPD) among women with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), or rheumatoid arthritis (RA), in comparison with a matched population without rheumatic diseases (RD).

The FRAX algorithm for risk prediction of major osteoporotic fractures and hip fractures accounts for several risk factors, including rheumatoid arthritis (RA), as individuals with RA have an excess burden of fractures. FRAX has not been validated in population-based RA cohorts in the US. We aimed to determine the accuracy of FRAX risk predictions for individuals with RA in the US.

To study clinical variables defining temporomandibular function in adults with juvenile idiopathic arthritis (JIA) and healthy controls.

To evaluate the relevance and clinical utility of Patient-Reported Outcomes Measurement Information System (PROMIS®) surveys in patients with systemic lupus erythematosus (SLE).

To analyse the Multidimensional Health Assessment Questionnaire (MDHAQ) in screening for anxiety in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), in comparison to the Hospital Anxiety and Depression Scale (HADS) as the reference standard.

Type I interferon (IFN-I) is thought to play a role in many systemic autoimmune diseases. IFN-I pathway activation is associated with pathogenic features, including the presence of autoantibodies and clinical phenotypes such as more severe disease with increased disease activity and damage. We will review the role and potential drivers of IFN-I dysregulation in five prototypic autoimmune diseases:

Antiphospholipid antibody (aPL) nephropathy (aPL-N) can be challenging to recognize due to lack of established classification or diagnostic criteria. As part of efforts to develop new antiphospholipid syndrome (APS) classification criteria (CC), the APS CC Renal Pathology subcommittee aimed to better characterize the entity of aPL-N.

We read with interest the recent publication by Lange and colleagues on the red cell distribution width (RDW) and absolute lymphocyte count (ALC) associated with biomarkers of inflammation and subsequent mortality in rheumatoid arthritis (RA).1 The authors concluded that RDW and ALC before disease-modifying antirheumatic drug (DMARD) therapy are associated with biomarkers of monocyte/macrophage inflammation

In a recent issue of The Journal of Rheumatology, Berard et al1 reported on the development of the Canadian recommendations for the screening, monitoring, and treatment of uveitis associated with juvenile idiopathic arthritis ( JIA).1 The guidance from this national multidisciplinary JIA-associated uveitis working group had a welcome and necessary focus on the importance of disease control but omitted

Chronic inflammatory conditions, including inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA), have a high burden among women of reproductive age. There has been significant interest in finding safe ways of controlling disease activity during pregnancy without adversely affecting the pregnancy or offspring.

OBJECTIVE Concerns about the affordability of medications are common in systemic lupus erythematosus (SLE), but the relationship between medication cost concerns and health outcomes is poorly understood. We assessed the association of self-reported medication cost concerns and patient-reported outcomes (PROs) in a multiethnic lupus cohort. METHODS The California Lupus Epidemiology Study is a cohort

Suboptimal treatment adherence has been reported in patients with arthritic diseases; is associated with psychological factors, including anxiety; and correlates with future treatment response.1,2 During the coronavirus disease 2019 (COVID-19) pandemic, patients who identified as clinically extremely vulnerable, including people prescribed ≥ 2 immunosuppressives, were advised to shield and continue

OBJECTIVE The diagnosis in the studies analyzing HLA of dermatomyositis (DM) was based on a combined clinical category of polymyositis/DM. This retrospective study investigated the associations of HLA with 5 DM-specific autoantibodies in Japanese patients diagnosed by muscle pathology. METHODS We diagnosed Japanese patients with DM based on sarcoplasmic expression of myxovirus resistance protein A